You are here

Nature medicine DOI:10.1038/nm.3352

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Publication TypeJournal Article
Year of Publication2013
AuthorsVaishnavi, A, Capelletti, M, Le, AT, Kako, S, Butaney, M, Ercan, D, Mahale, S, Davies, KD, Aisner, DL, Pilling, AB, Berge, EM, Kim, J, Sasaki, H, Park, SI, Kryukov, G, Garraway, LA, Hammerman, PS, Haas, J, Andrews, SW, Lipson, D, Stephens, PJ, Miller, VA, Varella-Garcia, M, Jänne, PA, Doebele, RC
JournalNature medicine
Date Published2013/10/27

We identified new gene fusions in patients with lung cancer harboring the kinase domain of the NTRK1 gene that encodes the high-affinity nerve growth factor receptor (TRKA protein). Both the MPRIP-NTRK1 and CD74-NTRK1 fusions lead to constitutive TRKA kinase activity and are oncogenic. Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity inhibited autophosphorylation of TRKA and cell growth. Tumor samples from 3 of 91 patients with lung cancer (3.3%) without known oncogenic alterations assayed by next-generation sequencing or fluorescence in situ hybridization demonstrated evidence of NTRK1 gene fusions.